XNAS
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | H1 2024 | — | -25.00 | — | $0 | — | +8.43% | -15.52% | -12.12% |
| 2024-04-19 | FY 2023 | — | -246.60 | — | $469,791 | — | +1.73% | +72.87% | +68.88% |
| 2023-09-29 |
| H1 2023 |
| — |
| -496.50 |
| — |
| $369,973 |
| — |
| -6.61% |
| -21.64% |
| -21.84% |
| 2023-05-22 | FY 2022 | — | -239.75 | — | $865,089 | — | +2.69% | -28.56% | -59.43% |
Showing last 4 quarters.